J&J li­cens­es LegoChem's Trop2 ADC for $100M up­front

John­son and John­son’s sub­sidiary Janssen is li­cens­ing a Trop2 di­rect­ed an­ti­body-drug con­ju­gate from South Ko­rea’s LegoChem Bio­sciences in a deal that could be worth as …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.